Bioequivalence of Celecoxib Capsules in Chinese Healthy Volunteers
Clinical Pharmacology in Drug Development · 2023
DOI: 10.1002/cpdd.1270 ↗Kurz gefasst
Äquivalenzstudie in der Zeitschrift Clinical Pharmacology in Drug Development, 2023. Verfasst von Lichun Dong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, China. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Celecoxib, East Asian People. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Celecoxib is a sulfanilamide nonsteroidal anti‐inflammatory drug that can selectively inhibit cyclooxygenase‐2 to inhibit prostaglandin production, achieving anti‐inflammatory and analgesic effects. This study investigated the pharmacokinetics, safety, and bioequivalence of a single oral dose of celecoxib capsule (the test or reference preparation) in healthy volunteers under fasting and fed conditions. A single‐center, randomized, open, single‐dose, double‐cycle crossover self‐control design was conducted: 40 healthy volunteers were enrolled in the fasting and fed groups, respectively. A completely randomized method was used, with one group taking the test celecoxib preparation (T) and the other taking the reference celecoxib preparation (R). During the administration period, the safety of the drug was evaluated simultaneously, and venous blood was collected at the corresponding time points. The concentration of celecoxib in plasma was measured by liquid chromatography–tandem mass spectrometry. The main pharmacokinetic parameters were logarithmically converted and analyzed for variance. The 90% confidence interval for the bioavailability of the T compared to the R was calculated using maximum drug plasma concentration, area under the plasma concentration–time curve from time zero to the last quantifiable concentration point, and area under the plasma concentration–time curve from time zero to infinity for a single oral dose in volunteers, and the data obtained were all between 80% and 125%, indicating that the T and R have bioequivalence and good safety during fasting and fed administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, China.
Zitieren
APA
Dong, L., Zhao, M., Huang, H., Guan, R., Li, R., Fan, Y., Feng, J., Zhang, J., Zou, W., Chen, J., Long, S., & He, J. (2023). Bioequivalence of Celecoxib Capsules in Chinese Healthy Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1270
Vancouver
Dong L, Zhao M, Huang H, Guan R, Li R, Fan Y, et al. Bioequivalence of Celecoxib Capsules in Chinese Healthy Volunteers. Clinical Pharmacology in Drug Development. 2023. doi:10.1002/cpdd.1270
BibTeX
@article{Dong2023,
author = {Dong, Lichun and Zhao, Mingxuan and Huang, Huiyuan and Guan, Runfang and Li, Ruixia and Fan, Yuxin and Feng, Jin and Zhang, Juan and Zou, Wenhong and Chen, Jiong and Long, Shuxian and He, Jianchang},
title = {Bioequivalence of Celecoxib Capsules in Chinese Healthy Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2023},
doi = {10.1002/cpdd.1270}
}
EUVIMED